<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intravenous (IV) iron products (use in adults)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intravenous (IV) iron products (use in adults)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Intravenous (IV) iron products (use in adults)</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="15%"></colgroup> <colgroup width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Trade (brand) name</td> <td class="subtitle1">Concentration of elemental iron</td> <td class="subtitle1">Dosing<br/> (adults)</td> <td class="subtitle1">Test dose</td> <td class="subtitle1">Premedication</td> </tr> <tr> <td>Ferric carboxymaltose (FCM)<sup>*</sup></td> <td>Injectafer (United States), Ferinject (United Kingdom and other countries)</td> <td>50 mg/mL</td> <td> <ul> <li>Weight ≥50 kg: 1 or 2 doses of 750 mg, given 7 or more days apart</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li>Weight &lt;50 kg: 1 or 2 doses of 15 mg/kg, given 7 or more days apart</li> </ul> </td> <td>Not required</td> <td rowspan="6"> <ul> <li>We do not routinely premedicate for any of the IV iron products.</li> <li>For patients with asthma or multiple drug allergies, we often give methylprednisolone and a histamine 2 (H2) receptor blocker prior to the iron infusion.</li> <li>For patients with inflammatory arthritis, we often give methylprednisolone followed by a brief course of oral prednisone.</li> <li>We do not give diphenhydramine as a premedication.</li> </ul> </td> </tr> <tr> <td>Ferric derisomaltose (previously called iron isomaltoside)</td> <td>Monoferric (United States, Canada), Monofer (United Kingdom, other countries)</td> <td>100 mg/mL</td> <td> <ul> <li>Weight ≥50 kg: Single dose of 1000 mg</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li>Weight ≥50 kg: Up to 3 doses of 500 mg given over 7 days</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li>Weight &lt;50 kg: Single dose of 20 mg/kg</li> </ul> </td> <td>Not required</td> </tr> <tr> <td>Ferric gluconate (FG)</td> <td>Ferrlecit</td> <td>12.5 mg/mL</td> <td> <ul> <li>Multiple doses of 125 to 250 mg</li> </ul> </td> <td>Not required, but recommended if the patient has a history of multiple drug allergies</td> </tr> <tr> <td>Ferumoxytol<sup>¶</sup></td> <td>Feraheme (United States), Rienso (United Kingdom and other countries)</td> <td>30 mg/mL</td> <td> <ul> <li>Single dose of 1020 mg</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li>2 doses of 510 mg, given 3 to 8 days apart</li> </ul> </td> <td>Not required</td> </tr> <tr> <td>Iron dextran, low molecular weight (LMW <span class="nowrap_whitespace">ID)<sup>Δ</sup></span></td> <td>INFeD (United States), Dexiron (Canada), CosmoFer (United Kingdom and other countries)</td> <td>50 mg/mL</td> <td> <ul> <li>Single dose of 1000 mg (diluted in 250 mL normal saline) given over 1 hour</li> </ul> <p class="extra_spacing"><strong>or</strong></p> <ul> <li>Multiple doses of 100 mg</li> </ul> </td> <td>Yes, 25 mg (0.5 mL) prior to the first dose</td> </tr> <tr> <td>Iron sucrose (IS)</td> <td>Venofer</td> <td>20 mg/mL</td> <td> <ul> <li>Multiple doses of 100 to 300 mg</li> </ul> </td> <td>Not required, but recommended if the patient has a history of multiple drug allergies</td> </tr> </tbody></table></div><div class="graphic_lgnd">Dosing information in this table is for adults and includes some dosing recommendations not listed in the approved product information. For all products, slow initial infusion is prudent; the patient is observed closely for infusion reactions. Refer to UpToDate for the management of iron deficiency and refer to the most recent product labeling for additional information. Product labeling for all of the products available in the United States is available on the US Food and Drug Administration website (<a href="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/" target="_blank">https://www.accessdata.fda.gov/scripts/cder/drugsatfda/</a>) or the National Library of Medicine (<a href="https://dailymed.nlm.nih.gov/dailymed/" target="_blank">https://dailymed.nlm.nih.gov/dailymed/</a>).</div><div class="graphic_footnotes"><p>* Ferric carboxymaltose can cause hypophosphatemia and should be avoided in individuals with hypophophatemia or at increased risk. Monitoring of serum phosphate is needed in individuals receiving more than one dose.</p>
<p>¶ Notify radiologist if patient has a magnetic resonance imaging (MRI) scan, including noncontrast scanning, within 3 months of ferumoxytol administration, as the properties of ferumoxytol affect the appearance of different imaging sequences.</p>
Δ High molecular weight iron dextran (HMW ID) is no longer available.</div><div id="graphicVersion">Graphic 106130 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
